Hancock B W, Bruce L, Richmond J
Br Med J. 1976 Aug 7;2(6031):351-2. doi: 10.1136/bmj.2.6031.351.
The leucocyte migration responses of patients with malignant lymphoma to an unidentified factor in Hodgkin's spleen tissue were serially studied and related to clinical progress. Initial sensitisation responses did not correlate with presenting histological or clinical status or with subsequent clinical progress. Enhancement of responses after treatment, however, was associated with good clinical progress. In patients who relapsed, sensitisation to spleen factor diminished, whereas responses were preserved at one year in those in maintained remission. Sensitisation to the splenic factor may be a useful index of response to treatment in patients with malignant lymphoma; diminishing sensitisation may indicate relapse.
对恶性淋巴瘤患者针对霍奇金脾脏组织中一种不明因子的白细胞迁移反应进行了系列研究，并与临床进展相关联。初始致敏反应与就诊时的组织学或临床状况以及随后的临床进展均无关联。然而，治疗后反应增强与良好的临床进展相关。在复发的患者中，对脾脏因子的致敏作用减弱，而在持续缓解一年的患者中反应得以保留。对脾脏因子的致敏作用可能是恶性淋巴瘤患者治疗反应的一个有用指标；致敏作用减弱可能预示复发。
